NCT07140757

Brief Summary

To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
55mo left

Started Aug 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress15%
Aug 2025Dec 2030

Study Start

First participant enrolled

August 18, 2025

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

August 22, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 26, 2025

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2030

Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

3.4 years

First QC Date

August 22, 2025

Last Update Submit

March 10, 2026

Conditions

Low RiskPapillary Thyroid CancerRadiofrequency Ablation

Outcome Measures

Primary Outcomes (1)

  • Health- related Quality of Life Questionnaires

    This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.

    Through study completion; an average of 1 year

Interventions

QuestionnaireOTHER

This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MD Anderson Cancer Center

You may not qualify if:

  • Participants meeting any of the following criteria will be excluded:
  • Participants considered unsuitable for RFA by the treating physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Thyroid Cancer, Papillary

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Adenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsThyroid NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Victoria E Banuchi, MD

    M.D. Anderson Cancer Center

    STUDY DIRECTOR

Central Study Contacts

Victoria E Banuchi, MD

CONTACT

346-217-8668vebanuchi@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2025

First Posted

August 26, 2025

Study Start

August 18, 2025

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2030

Last Updated

March 11, 2026

Record last verified: 2026-03

Locations

US(1)